{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/prostatitis-chronic/management/managing-chronic-prostatitis/","result":{"pageContext":{"chapter":{"id":"dbc1e2eb-5ed6-5e3b-9aa6-6f4a53bae15e","slug":"managing-chronic-prostatitis","fullItemName":"Scenario: Managing chronic prostatitis","depth":2,"htmlHeader":"<!-- begin field b3bfa5ca-a6d1-4797-b925-c4ad98ea75a2 --><h2>Scenario: Managing chronic prostatitis</h2><!-- end field b3bfa5ca-a6d1-4797-b925-c4ad98ea75a2 -->","summary":"Covers the management of men with chronic prostatitis.","htmlStringContent":"<!-- begin item 192861fd-87e2-42a7-9dff-4f27dd92bde8 --><!-- begin field 26a1bf67-e870-48f6-9103-acbc015c7232 --><p>From age 16 years onwards (Male).</p><!-- end field 26a1bf67-e870-48f6-9103-acbc015c7232 --><!-- end item 192861fd-87e2-42a7-9dff-4f27dd92bde8 -->","topic":{"id":"c4c9527b-558e-5f8e-bc17-8e290dcde258","topicId":"e7c47213-5bd0-4104-8047-fdc108a48fed","topicName":"Prostatitis - chronic","slug":"prostatitis-chronic","lastRevised":"Last revised in September 2019","chapters":[{"id":"db8b7f60-5def-5da6-8f5a-97b134fe81af","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"261b0e99-ad07-59aa-82ad-fa8c5e297c03","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"191f6daf-33c8-5a36-9298-deb70f2118f9","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3196f07a-652b-594b-a01b-c5adf6819612","slug":"changes","fullItemName":"Changes"},{"id":"cb3c96a5-276d-5602-88a2-6fe23e9db68a","slug":"update","fullItemName":"Update"}]},{"id":"71da42c9-a078-59ae-90c6-752133b53212","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"aec7f6cf-32f0-5cb8-997e-4fef498eea4a","slug":"goals","fullItemName":"Goals"},{"id":"3afbaae7-ae1e-5df4-87a4-e8fcadd24ce9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"87d31fcb-2e1a-5f5f-b2b3-3cebf26dbf5e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b0e77d09-ef7a-52ce-a61d-d74872fcd77f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"73212593-e3d8-52ec-9384-1ee26a9e0290","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"59aaca07-0adb-5035-afea-fd747f067bc8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"864060e0-9a10-5069-9b80-daf6551f49b4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"120b86df-be4c-54e8-ab8a-7edcad60de73","slug":"definition","fullItemName":"Definition"},{"id":"a35c2de7-75f2-59f4-9df6-6115e92ac1f7","slug":"causes","fullItemName":"Causes"},{"id":"3aa8e065-e5d9-587b-92fa-8e1824a53f6e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"34308471-71dc-5ccd-bf18-de90bce09174","slug":"prognosis","fullItemName":"Prognosis"},{"id":"6bcf89d2-7be0-5893-bcef-296b2b00b23e","slug":"complications","fullItemName":"Complications"}]},{"id":"e0b8b43d-8013-564a-b64b-23866b939127","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"5803967f-79d1-596c-8fb4-58eb0581f053","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"2901399a-1d1a-5b5e-ba74-a8e2973308cc","slug":"assessment","fullItemName":"Assessment"},{"id":"07fe1726-43db-50e8-854d-9e8d2048398c","slug":"investigations","fullItemName":"Investigations"},{"id":"3cf83ed6-63bf-58b4-97f7-98cd7d6815da","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"dc9db115-7acf-5a8a-9dd1-f6bf8dd93454","fullItemName":"Management","slug":"management","subChapters":[{"id":"dbc1e2eb-5ed6-5e3b-9aa6-6f4a53bae15e","slug":"managing-chronic-prostatitis","fullItemName":"Scenario: Managing chronic prostatitis"}]},{"id":"c609cd7e-5825-5ffb-83e8-ba87b7f7806d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"035b193a-907c-5212-99c7-e8a8926b1594","slug":"paracetamol-ibuprofen-codeine","fullItemName":"Paracetamol, ibuprofen, and codeine"},{"id":"f4e7b4f3-38ad-521e-bb43-4c48ac37724f","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"24c19a61-fe65-594c-a4e5-ab3b500281e4","slug":"trimethoprim","fullItemName":"Trimethoprim"},{"id":"2a603a06-dc49-5056-bf3b-1492b6300035","slug":"azithromycin","fullItemName":"Azithromycin"}]},{"id":"39e951b0-a3a9-5bae-8465-8d5b1ac9504b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d8eb1d6d-d3f5-593e-bcbc-4214d26beee2","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a9bd9455-225c-5705-8101-1b4f3177119c","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3984c05f-a691-5d06-9587-785be5667206","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e6bedf32-0ef7-5118-b6e2-fc3c2631a8c3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"1405259b-4bc7-5907-af93-234db06e958f","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ad44cee6-1d13-5c9e-9587-6de26a5b22fd","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"160b464d-6dc9-5bb7-9156-90aa025b130c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"dc9db115-7acf-5a8a-9dd1-f6bf8dd93454","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"9706c751-948d-5e8f-8cd5-9172c2c9e5b5","slug":"managing-chronic-prostatitis","fullItemName":"Managing chronic prostatitis","depth":3,"htmlHeader":"<!-- begin field de4da3c5-7c17-4678-8ee5-63cd5da95017 --><h3>How should I manage a man with suspected chronic prostatitis?</h3><!-- end field de4da3c5-7c17-4678-8ee5-63cd5da95017 -->","summary":null,"htmlStringContent":"<!-- begin item 2085b672-0155-4001-8968-931d60a9f208 --><!-- begin field 9f174cf6-9ec5-4a7c-a9f1-4b47de97c0d6 --><ul><li><strong>Explain to the man that:</strong><ul><li>The cause is not always understood, but is thought to be multifactorial.</li><li>The condition is chronic and treatment can be difficult, but most men notice improvement within six months.</li><li>Treatment is often more about controlling symptoms rather than effecting an immediate cure.</li></ul></li><li><strong>Reassure the man about the nature of the disease and that chronic prostatitis is not cancer and is very rarely caused by a sexually transmitted infection. </strong></li><li><strong>Provide information about self-help resources:</strong><ul><li>Prostate Cancer UK provides online information and support on its website (<a href=\"http://prostatecanceruk.org/information/prostatitis\" data-hyperlink-id=\"52123ac2-5398-4004-a370-a98d0092694c\">www.prostatecanceruk.org</a>). </li><li>The NHS provides <a href=\"https://www.nhs.uk/conditions/\" data-hyperlink-id=\"4b27ef82-0865-444b-8f63-a98d00926a12\">online</a> information for men with chronic prostatitis.</li></ul></li><li><strong>For men with suspected chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS):</strong><ul><li>Consider using the Urinary, Psychosocial, Organ-specific, Infection, Neurological/systemic, and Tenderness (<a href=\"http://www.upointmd.com/\" data-hyperlink-id=\"7c594c95-8f44-424d-b63c-aac700a336ec\">UPOINT</a>) classification system to stratify patients into specific symptom-led phenotypes.<ul><li>The UPOINT approach to symptom evaluation can direct which treatments to use. </li></ul></li></ul></li><li><strong>Most men with CP/CPPS require multimodal treatment aimed at the main symptoms (taking comorbidity into account). Options include offering: </strong><ul><li>Paracetamol and/or a nonsteroidal anti-inflammatory drug (NSAID) for pain relief. <ul><li>Do not prescribe opioids.</li><li>For men with suspected neuropathic pain, seek advice from a pain specialist. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/neuropathic-pain-drug-treatment/\">Neuropathic pain - drug treatment</a>.</li></ul></li><li>An alpha-blocker for 4–6 weeks if significant lower urinary tract symptoms (LUTS) are present. <ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/luts-in-men/\">LUTS in men</a>.</li></ul></li><li>Targeted cognitive behavioural therapy, counselling and antidepressants for men with psychosocial symptoms (for example, depression, stress and poor coping mechanisms). </li><li>A single course of antibiotics, if symptoms have been present for less than 6 months. Antibiotic options include: <ul><li>Trimethoprim 200 mg twice a day for 4–6 weeks, or </li><li>Doxycycline 100 mg twice daily for 4–6 weeks. </li></ul></li><li>A stool softener such as lactulose or docusate if defecation is painful. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/constipation/\">Constipation</a>. </li><li>Acupuncture. </li></ul></li><li><strong>Refer to a urologist if: </strong><ul><li>There is diagnostic uncertainty.</li><li>Symptoms are severe (use clinical judgement to determine the urgency of referral). </li><li>Symptoms persist after initial management. </li></ul></li><li><strong>For men with suspected chronic bacterial prostatitis (a history of urinary tract infection, or an episode of acute prostatitis within the last 12 months):</strong><ul><li><strong>​​​​</strong>Refer to a urologist for specialist assessment (use clinical judgement to determine the urgency of referral).</li><li>If defecation is painful — offer a stool softener such as lactulose or docusate. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/constipation/\">Constipation</a>. </li><li>If the man is in pain, prescribe paracetamol and/or a nonsteroidal anti-inflammatory drug (NSAID).<ul><li>For men with neuropathic pain, seek advice from a pain specialist. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/neuropathic-pain-drug-treatment/\">Neuropathic pain - drug treatment</a>.</li></ul></li><li>While awaiting referral prescribe a single course of antibiotic treatment. Options include: <ul><li>Trimethoprim 200 mg twice a day for 4-6 weeks, or</li><li>Doxycycline 100 mg twice daily for 4–6 weeks.</li></ul></li></ul></li></ul><!-- end field 9f174cf6-9ec5-4a7c-a9f1-4b47de97c0d6 --><!-- end item 2085b672-0155-4001-8968-931d60a9f208 -->","subChapters":[{"id":"7c544585-b0be-5c4e-a35e-e6f3e816ce0c","slug":"basis-for-recommendation-f74","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field fa8ce435-6ea9-493d-b7e2-9b96fd9c2291 --><h4>Basis for recommendation</h4><!-- end field fa8ce435-6ea9-493d-b7e2-9b96fd9c2291 -->","summary":null,"htmlStringContent":"<!-- begin item f7441f89-222b-4838-b460-1907c7f34965 --><!-- begin field 6f7071d1-35d1-47c2-aa75-2a832e11fe0e --><p>These recommendations are based on the European Association of Urology (EAU) guidelines <em>Chronic pelvic pain</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">EAU, 2019a</a>] and <em>Urological infections</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">EAU, 2019b</a>], the Royal College of General Practitioners and British Association for Sexual Health and HIV guideline <em>Sexually transmitted infections in primary care </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">Lazaro, 2013</a>], the UK consensus guideline <em>Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">Rees et al, 2014</a>], expert opinion in narrative reviews <em>Contemporary Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">Magistro, 2016</a>], <em>Common Questions About Chronic Prostatitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">Holt, 2016</a>], <em>Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">DeWitt-Foy, 2019</a>], and what CKS considers to be good clinical practice.</p><p><strong>UPOINTS classification </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">Magistro, 2016</a>]</p><ul><li>UPOINT is able to discriminate clinical phenotypes, and positive domains appear to correlate with symptom severity and duration of disease. Clinical results indicate a correlation between the number of positive UPOINT domains and total NIH-CPSI score. </li><li>First studies suggest that the multimodal treatment guided by UPOINT leads to a significant improvement of symptoms and quality of life. In a prospective study including a cohort of 100 men positive for a minimum of three UPOINT domains, clinical response to a phenotypically directed multimodal treatment was evaluated by a change in NIH-CPSI score. Almost 84% of men met the primary end point of at least a 6-point change in total NIH-CPSI score with a median follow-up of 50 wk. All NIH-CPSI subdomains comprising scores for pain, urinary symptoms, and quality of life were significantly improved (each p < 0.0001).</li><li>An updated classification system which includes a sexual dysfunction domain (UPOINTs) has been proposed. Although first results are promising, further clinical RCTs are warranted for a complete validation of the UPOINTs approach. </li></ul><h5>Treatment of CP/CPPS</h5><ul><li>The evidence for CP/CPPS treatment is poor, with small studies showing small effects, suggesting any benefit may be a placebo effect [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">Holt, 2016</a>]. </li><li>Due to the heterogeneity and the still elusive pathophysiology of CP/CPPS, the establishment of effective treatment modalities remains challenging. A multitude of clinical trials failed to identify an efficient primary treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">Magistro, 2016</a>].  </li><li>The recommendation to offer a 4–6 week trial of an alpha-blocker is based on expert opinion from the UK consensus guideline <em>Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">Rees et al, 2014</a>] and is supported by guidelines published by the European Association of Urology (EAU) <em>Guidelines on chronic pelvic pain </em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">EAU, 2019a</a>]. <ul><li>A network meta-analysis that pooled data from five randomized controlled trials (RCTs) (n = 568) found that compared with placebo, alpha-blockers (alfuzosin, doxazosin, tamsulosin, and terazosin) significantly reduced total symptoms score (-1.7, 95% CI -2.8 to -0.6), pain (-1.1, 95% CI, -1.8 to -0.3), voiding (-1.4 95% CI, -2.3 to -0.5), and quality of life (-1.0 95% CI, -1.8 to -0.2) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">Anothaisintawee et al, 2011</a>]. It also found that combination therapy of antibiotics with α-blockers was more beneficial. </li><li>Pooled data from another meta-analysis (8 trials, n = 770) also found that alpha-blockers significantly reduced the total symptom score (-4.80, 95% CI -7.08 to -2.58) when compared with placebo. However, the authors also noted a significant placebo effect and they did not consider a 4.8 reduction in total symptom score to be clinically significant [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">Cohen et al, 2012</a>]. </li></ul></li></ul><p><strong>Antibiotics for treating chronic bacterial prostatitis (CBP) or CP/CPPS</strong></p><ul><li>The EAU guideline <em>Chronic Pelvic Pain </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">EAU, 2019a</a>] recommends a quinolone or tetracycline antibiotic over a minimum of six weeks in treatment-naïve men with a duration of pelvic pain syndrome (PPS) of less than one year, and the guide on <em>Urological infections</em> recommends using a quinolone first line and a macrolide (e.g. azithromycin) or a tetracycline (e.g. doxycycline) if intracellular bacteria have been identified as the causative agent of CBP. </li><li>The UK consensus guideline <em>Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">Rees et al, 2014</a>], advises that antimicrobial therapy may have a moderate effect on total urinary, pain and quality of life scores in me with CBP and CP/CPPS and recommends offering a quinolone (e.g. ciprofloxacin or ofloxacin) for 4–6 weeks as first-line therapy in men with early-stage CBP or CP/CPPS, and either trimethoprim or doxycycline as second-line options. </li><li>However, advice from the MHRA and European Medicines Agency has advised that EMA has reviewed serious, disabling and potentially permanent side effects with quinolone and fluoroquinolone antibiotics given by mouth, injection or inhalation.<br>The <a data-hyperlink-id=\"6d212902-8cbc-4c5d-b921-aa1600db9e0b\" href=\"https://www.ema.europa.eu/en/glossary/chmp\" target=\"_blank\" title=\"Committee for Medicinal Products for Human Use -  the committee that is responsible for preparing the Agency's opinions on questions concerning human medicines.For more information, see Committee for Medicinal Products for Human Use (CHMP).\">CHMP</a> confirmed that the use of the remaining fluoroquinolone antibiotics should be restricted. Fluoroquinolone should <strong>not</strong> be used to [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">EMA, 2019</a>]: <ul><li>Treat infections that might get better without treatment or are not severe (such as throat infections).</li><li>Treat non-bacterial infections, e.g. non-bacterial (chronic) prostatitis.</li><li>Prevent traveller’s diarrhoea or recurring lower urinary tract infections (urine infections that do not extend beyond the bladder).</li><li>Treat mild or moderate bacterial infections unless other antibacterial medicines commonly recommended for these infections cannot be used.</li></ul></li><li>The recommendation to offer trimethoprim or doxycycline as treatment options for men with CP/CPPS is based on the EMA advice and the alternatives to quinolones recommended in the EAU guidelines and the consensus guideline. </li></ul><h5>Acupuncture</h5><ul><li>The recommendation to consider offering acupuncture is based on the EAU guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">EAU, 2019a</a>], and a Cochrane systematic review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">Franco, 2018</a>], which found that:<ul><li>In three studies (n = 204) based on short-term follow-up, acupuncture probably leads to clinically meaningful reduction in prostatitis symptoms compared with sham procedure (mean difference [MD] in total NIH-CPSI score -5.79, 95% confidence interval [CI] -7.32 to -4.26).</li><li>In two studies (n = 78) acupuncture may also lead to a clinically meaningful reduction in prostatitis symptoms compared with standard medical therapy (MD -6.05, 95% CI -7.87 to -4.24).</li></ul></li></ul><h5>Referral of men with CBP to urology</h5><ul><li>Men with CBP commonly present with recurrent urinary tract infections which require further assessment by a urologist to exclude an underlying urological abnormality. The recommendation to refer for urological assessment is based on expert opinion in COMPASS <em>Therapeutic notes on the management of bacterial urinary tract infections in primary care </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">COMPASS, 2012</a>], and expert opinion in the Scottish Intercollegiate Guidelines Network (SIGN) national clinical guideline <em>Management of suspected bacterial urinary tract infection in adults </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-chronic/references/\">SIGN, 2012</a>]. COMPASS recommends looking for underlying causes of recurrent UTI such as prostatic enlargement due to cancer or benign prostatic hypertrophy, urinary calculi, and bladder cancer, which require specialist referral to confirm these diagnoses.</li></ul><!-- end field 6f7071d1-35d1-47c2-aa75-2a832e11fe0e --><!-- end item f7441f89-222b-4838-b460-1907c7f34965 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}